Yuichiro Ohe Selected Research

Yuichiro Ohe Research Topics

Disease

155	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2022 - 02/2002
114	Neoplasms (Cancer) 07/2022 - 01/2002
44	Lung Neoplasms (Lung Cancer) 12/2022 - 05/2002
23	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2021 - 05/2002
18	Interstitial Lung Diseases (Interstitial Lung Disease) 07/2022 - 07/2004
17	Neutropenia 12/2020 - 02/2005
16	Disease Progression 05/2022 - 07/2006
13	Adenocarcinoma of Lung 01/2021 - 02/2007
12	Neoplasm Metastasis (Metastasis) 01/2021 - 05/2007
11	Diarrhea 06/2022 - 05/2007
9	Carcinoma (Carcinomatosis) 01/2022 - 08/2005
9	Adenocarcinoma 10/2020 - 05/2002
8	Thymoma (Thymic Carcinoma) 10/2020 - 05/2015
7	Febrile Neutropenia 12/2020 - 10/2015
6	Exanthema (Rash) 01/2022 - 09/2009
5	Malignant Mesothelioma 06/2021 - 06/2019
5	Radiation Pneumonitis 01/2021 - 07/2006
5	Drug-Related Side Effects and Adverse Reactions 08/2020 - 03/2007
5	Thrombocytopenia (Thrombopenia) 01/2020 - 12/2009
4	Pneumonia (Pneumonitis) 10/2022 - 01/2012
4	Anemia 01/2020 - 08/2006
3	Lymphoma (Lymphomas) 01/2022 - 10/2006
3	Nausea 04/2021 - 10/2018
3	Vomiting 04/2021 - 10/2018
3	Infections 01/2021 - 07/2012
3	Fever (Fevers) 12/2020 - 02/2004
3	Ovarian Neoplasms (Ovarian Cancer) 12/2020 - 06/2010
3	Fatigue 10/2020 - 10/2006
3	Lung Injury 11/2019 - 07/2006
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2015 - 12/2009
2	Stomatitis 06/2022 - 05/2022
2	Cachexia 02/2022 - 01/2014
2	Dermatitis 05/2021 - 06/2016

Drug/Important Bio-Agent (IBA)

40	ErbB Receptors (EGF Receptor)IBA 01/2022 - 10/2005
37	Cisplatin (Platino)FDA LinkGeneric 04/2022 - 02/2002
30	Tyrosine Kinase InhibitorsIBA 02/2022 - 10/2006
27	PlatinumIBA 04/2022 - 05/2002
27	NivolumabIBA 01/2022 - 01/2016
26	Gefitinib (Iressa)FDA Link 04/2019 - 05/2002
21	Pharmaceutical PreparationsIBA 07/2022 - 01/2002
19	Carboplatin (JM8)FDA LinkGeneric 04/2021 - 01/2008
19	Paclitaxel (Taxol)FDA LinkGeneric 01/2017 - 12/2003
18	osimertinibIBA 06/2022 - 04/2015
16	Irinotecan (Camptosar)FDA LinkGeneric 12/2020 - 01/2002
13	pembrolizumabIBA 10/2022 - 01/2017
12	B7-H1 AntigenIBA 03/2022 - 05/2015
12	Docetaxel (Taxotere)FDA Link 01/2020 - 02/2002
11	Immune Checkpoint InhibitorsIBA 03/2022 - 01/2016
11	Biomarkers (Surrogate Marker)IBA 11/2021 - 01/2011
10	amrubicinIBA 11/2019 - 09/2010
10	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2019 - 10/2005
9	alectinibIBA 05/2022 - 06/2013
9	LigandsIBA 01/2022 - 05/2015
8	Alanine Transaminase (SGPT)IBA 06/2022 - 12/2003
8	Etoposide (VP 16)FDA LinkGeneric 12/2020 - 05/2002
7	Monoclonal AntibodiesIBA 06/2021 - 01/2016
7	CrizotinibIBA 07/2019 - 06/2013
6	durvalumabIBA 04/2022 - 01/2020
6	Pemetrexed (MTA)FDA Link 01/2020 - 07/2008
5	Aspartate Aminotransferases (Aspartate Transaminase)IBA 06/2022 - 01/2019
5	Gemcitabine FDA Link 04/2021 - 02/2002
5	Proteins (Proteins, Gene)FDA Link 10/2020 - 02/2007
5	Anaplastic Lymphoma KinaseIBA 01/2020 - 02/2016
4	Antineoplastic Agents (Antineoplastics)IBA 07/2022 - 08/2006
4	Cytochrome P-450 CYP3AIBA 04/2022 - 02/2005
4	AntiemeticsIBA 04/2022 - 10/2018
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 07/2006
4	Bevacizumab (Avastin)FDA Link 10/2019 - 12/2016
4	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2012
4	Biological ProductsIBA 01/2013 - 09/2007
3	Aprepitant (Emend)FDA Link 04/2022 - 01/2020
3	Dexamethasone (Maxidex)FDA LinkGeneric 04/2022 - 02/2016
3	CytokinesIBA 02/2022 - 01/2002
3	SteroidsIBA 05/2021 - 07/2006
3	130-nm albumin-bound paclitaxelIBA 04/2021 - 06/2012
3	AntibodiesIBA 01/2021 - 12/2015
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2020 - 04/2002
3	Olanzapine (Zyprexa)FDA Link 01/2020 - 08/2016
3	amrubicinolIBA 11/2019 - 04/2012
3	Cadherins (E-Cadherin)IBA 08/2015 - 06/2012
3	Vinorelbine (Navelbine)FDA LinkGeneric 02/2012 - 08/2004
3	Hemoglobins (Hemoglobin)IBA 06/2010 - 08/2006
2	AZD 6244IBA 06/2022 - 05/2022
2	selpercatinibIBA 06/2022 - 01/2020
2	EnzymesIBA 04/2022 - 02/2005
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2022 - 01/2002
2	IpilimumabIBA 01/2022 - 01/2022
2	Investigational DrugsIBA 04/2021 - 03/2016
2	C-Reactive ProteinIBA 04/2021 - 12/2020

Therapy/Procedure

74	Therapeutics 12/2022 - 07/2004
67	Drug Therapy (Chemotherapy) 04/2022 - 02/2002
29	Radiotherapy 01/2022 - 07/2004
25	Chemoradiotherapy 04/2022 - 08/2003
6	Combination Drug Therapy (Combination Chemotherapy) 01/2022 - 12/2004
6	Immunotherapy 11/2021 - 05/2015
3	Molecular Targeted Therapy 01/2022 - 12/2015
3	Aftercare (After-Treatment) 01/2021 - 12/2013
3	Adjuvant Chemotherapy 12/2020 - 05/2016
2	Palliative Care (Palliative Therapy) 04/2022 - 11/2020
2	Activities of Daily Living (ADL) 04/2021 - 06/2017